{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:45:04Z","timestamp":1790289904597,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["2R01DA031725"],"award-info":[{"award-number":["2R01DA031725"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA064144-01"],"award-info":[{"award-number":["1R01DA064144-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA060632-01A1"],"award-info":[{"award-number":["1R01DA060632-01A1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R21DA061309"],"award-info":[{"award-number":["1R21DA061309"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pharmr.2026.100145","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:39:10Z","timestamp":1779925150000},"page":"100145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2035-5642","authenticated-orcid":false,"given":"Alexandra N.","family":"Johansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-2798","authenticated-orcid":false,"given":"Mark A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-0160","authenticated-orcid":false,"given":"William W.","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharmr.2026.100145_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2105\/AJPH.2022.307212","article-title":"Methamphetamine-related mortality in the united states: co-involvement of heroin and fentanyl, 1999-2021","volume":"113","author":"Hoopsick","year":"2023","journal-title":"Am J Public Health"},{"key":"10.1016\/j.pharmr.2026.100145_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature","volume":"143","author":"Courtney","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/npp.2012.179","article-title":"An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans","volume":"38","author":"Dean","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmr.2026.100145_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.irn.2015.02.004","article-title":"Neuropsychiatric adverse effects of amphetamine and methamphetamine","volume":"120","author":"Harro","year":"2015","journal-title":"Int Rev Neurobiol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100145_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/ATVBAHA.119.312461","article-title":"Methamphetamine use and cardiovascular disease: in search of answers","volume":"39","author":"Kevil","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.121.000767","article-title":"Methamphetamine dysregulation of the central nervous system and peripheral immunity","volume":"379","author":"Miller","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100145_bib9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","article-title":"Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review","volume":"77","author":"Paulus","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100145_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsab001","article-title":"Methamphetamine and sleep impairments: neurobehavioral correlates and molecular mechanisms","volume":"44","author":"Vrajov\u00e1","year":"2021","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/09595230801923702","article-title":"Major physical and psychological harms of methamphetamine use","volume":"27","author":"Darke","year":"2008","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.pharmr.2026.100145_bib12","series-title":"Drugs, Addiction, and the Brain","first-page":"93","article-title":"Psychostimulants","author":"Koob","year":"2014"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/jpet.119.258970","article-title":"The role of biogenic amine transporters in trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity","volume":"371","author":"Miner","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/jnp.15.3.317","article-title":"Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review","volume":"15","author":"Nordahl","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100145_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg-Martin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.pharmr.2026.100145_bib17","series-title":"StatPearls","article-title":"Biochemistry, Dopamine Receptors","author":"Bhatia","year":"2023"},{"key":"10.1016\/j.pharmr.2026.100145_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/7854_2022_347","article-title":"Current perspectives on selective dopamine d3 receptor antagonists\/partial agonists as pharmacotherapeutics for opioid and psychostimulant use disorders","volume":"60","author":"Newman","year":"2023","journal-title":"Curr Top Behav Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/adb.12512","article-title":"Dopamine D1 or D2 receptor-expressing neurons in the central nervous system","volume":"23","author":"Wei","year":"2018","journal-title":"Addict Biol"},{"key":"10.1016\/j.pharmr.2026.100145_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518779829","article-title":"Physiological and functional basis of dopamine receptors and their role in neurogenesis: possible implication for Parkinson\u2019s disease","volume":"12","author":"Mishra","year":"2018","journal-title":"J Exp Neurosci"},{"key":"10.1016\/j.pharmr.2026.100145_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pbb.2017.09.009","article-title":"21st century neurobehavioral theories of decision making in addiction: review and evaluation","volume":"164","author":"Bickel","year":"2018","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100145_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0163-7258(87)90108-2","article-title":"The role of reward pathways in the development of drug dependence","volume":"35","author":"Wise","year":"1987","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bcp.2007.08.003","article-title":"Monoamine transporters and psychostimulant addiction","volume":"75","author":"Howell","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1423-0127-18-83","article-title":"Methamphetamine-induced changes in the striatal dopamine pathway in \u03bc-opioid receptor knockout mice","volume":"18","author":"Park","year":"2011","journal-title":"J Biomed Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100145_bib25","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1038\/s41380-022-01596-6","article-title":"The relationship between glutamate, dopamine, and cortical gray matter: a simultaneous PET-MR study","volume":"27","author":"Rogeau","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100145_bib26","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.3390\/ijms21186491","article-title":"SCH23390 reduces methamphetamine self-administration and prevents methamphetamine-induced striatal LTD","volume":"21","author":"Avchalumov","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100145_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FBP.0b013e328333a28d","article-title":"Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats","volume":"20","author":"Brennan","year":"2009","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100145_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4028\/www.scientific.net\/AMR.998-999.169","article-title":"l-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates methamphetamine self-administration in rats","volume":"998\u2013999","author":"Yue","year":"2014","journal-title":"Adv Mater Res"},{"key":"10.1016\/j.pharmr.2026.100145_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejphar.2014.09.026","article-title":"A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats","volume":"743","author":"Chen","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"2\u20133","key":"10.1016\/j.pharmr.2026.100145_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2011.02.046","article-title":"Dopamine D3 receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats","volume":"659","author":"Higley","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100145_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pbb.2016.01.010","article-title":"Levo-tetrahydropalmatine, a natural, mixed dopamine receptor antagonist, inhibits methamphetamine self-administration and methamphetamine-induced reinstatement","volume":"144","author":"Gong","year":"2016","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmr.2026.100145_bib32","first-page":"71","article-title":"The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse","volume":"69","author":"Nickell","year":"2014","journal-title":"Adv Pharmacol San Diego Calif"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008790","article-title":"Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat","volume":"5","author":"Krasnova","year":"2010","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100145_bib34","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998","article-title":"Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428","volume":"18","author":"McCann","year":"1998","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0006-8993(82)90198-6","article-title":"Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain","volume":"235","author":"Ricaurte","year":"1982","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.158.3.377","article-title":"Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers","volume":"158","author":"Volkow","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100145_bib37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/0028-3908(89)90130-5","article-title":"Methamphetamine-induced neuronal damage: a possible role for free radicals","volume":"28","author":"De Vito","year":"1989","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-2999(99)00094-1","article-title":"Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine","volume":"371","author":"Stefanski","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-006-0330-6","article-title":"Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers","volume":"185","author":"Johanson","year":"2006","journal-title":"Psychopharmacology"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100145_bib40","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001","article-title":"Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence","volume":"21","author":"Volkow","year":"2001","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archpsyc.63.1.90","article-title":"Brain serotonin transporter density and aggression in abstinent methamphetamine abusers","volume":"63","author":"Sekine","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.001","article-title":"The role of human drug self-administration procedures in the development of medications","volume":"96","author":"Comer","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jeab.744","article-title":"Clinical neuropharmacology of cocaine reinforcement: a narrative review of human laboratory self-administration studies","volume":"117","author":"Regnier","year":"2022","journal-title":"J Exp Anal Behav"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addict Biol"},{"key":"10.1016\/j.pharmr.2026.100145_bib45","article-title":"New medications development for smoking cessation","volume":"7","author":"Lengel","year":"2023","journal-title":"Addict Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \"pipeline\" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2026.100145_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108307","article-title":"Contingency management for the treatment of methamphetamine use disorder: a systematic review","volume":"216","author":"Brown","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmr.2026.100145_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108904","article-title":"Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders","volume":"226","author":"Amin-Esmaeili","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib49","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1360-0443.2011.03473.x","article-title":"Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials","volume":"107","author":"Donovan","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.pharmr.2026.100145_bib50","series-title":"Stimulant Use Disorders: Developing Drugs for Treatment","year":"2023"},{"key":"10.1016\/j.pharmr.2026.100145_bib51","article-title":"Making addiction treatment more realistic and pragmatic: the perfect should not be the enemy of the good","author":"Volkow","year":"2022","journal-title":"Health Aff Forefr"},{"key":"10.1016\/j.pharmr.2026.100145_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugalcdep.2014.01.012","article-title":"Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes","volume":"137","author":"Carroll","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100145_bib53","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1080\/10826084.2024.2401341","article-title":"On the value of measuring recent drug use by self-reports and urinalysis in clinical trials","volume":"59","author":"Wish","year":"2024","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.pharmr.2026.100145_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173803","article-title":"Human laboratory models of reward in substance use disorder","volume":"241","author":"Johansen","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmr.2026.100145_bib55","first-page":"43","article-title":"Historical perspectives on the use of subjective effects measures in assessing the abuse potential of drugs","volume":"92","author":"Jaffe","year":"1989","journal-title":"NIDA Res Monogr"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100145_bib56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamapsychiatry.2022.1240","article-title":"Association of drug cues and craving with drug use and relapse: a systematic review and meta-analysis","volume":"79","author":"Vafaie","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1369-1600.2008.00121.x","article-title":"Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls","volume":"14","author":"Haney","year":"2009","journal-title":"Addict Biol"},{"issue":"5-6","key":"10.1016\/j.pharmr.2026.100145_bib58","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FBP.0b013e3283641c3d","article-title":"A review of human drug self-administration procedures","volume":"24","author":"Jones","year":"2013","journal-title":"Behav Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00405254","article-title":"Self-administration of psychoactive substances by the monkey","volume":"16","author":"Deneau","year":"1969","journal-title":"Psychopharmacologia"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","article-title":"Controversies in translational research: drug self-administration","volume":"199","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmr.2026.100145_bib61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.pa.09.040169.002411","article-title":"Self administration of and behavioral dependence on drugs","volume":"9","author":"Schuster","year":"1969","journal-title":"Annu Rev Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0091-3057(96)00445-5","article-title":"A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement","volume":"57","author":"Arnold","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","volume":"66","author":"Richardson","year":"1996","journal-title":"J Neurosci Methods"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100145_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s44159-023-00167-y","article-title":"A contextualized reinforcer pathology approach to addiction","volume":"2","author":"Acuff","year":"2023","journal-title":"Nat Rev Psychol"},{"key":"10.1016\/j.pharmr.2026.100145_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173511","article-title":"Demand and cross-price elasticity of cocaine and social contact in a free-operant procedure of nonexclusive choice","volume":"222","author":"Smith","year":"2023","journal-title":"Pharmacol Biochem Behav"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100145_bib66","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1360-0443.2007.02011.x","article-title":"Self-administration of drugs in animals and humans as a model and an investigative tool","volume":"102","author":"Panlilio","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.pharmr.2026.100145_bib67","series-title":"Psychiatric Disorders: Methods and Protocols","first-page":"195","article-title":"The human laboratory and drug development in alcohol use disorder: recent updates","author":"Chukwueke","year":"2019"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100145_bib68","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1360-0443.2005.01232.x","article-title":"Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers","volume":"100","author":"Donny","year":"2005","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-3565(25)32374-8","article-title":"Operant analysis of human heroin self-administration and the effects of naltrexone","volume":"216","author":"Mello","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib70","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-013-3120-y","article-title":"The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research","volume":"229","author":"Bossert","year":"2013","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41386-018-0196-4","article-title":"Novel models of drug relapse and craving after voluntary abstinence","volume":"44","author":"Venniro","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib72","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1124\/pharmrev.120.000191","article-title":"Animal models of drug relapse and craving after voluntary abstinence: a review","volume":"73","author":"Fredriksson","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2026.100145_bib73","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib74","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/add.12073","article-title":"Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial","volume":"108","author":"Coffin","year":"2013","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/13651501.2012.667116","article-title":"A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis","volume":"17","author":"Sulaiman","year":"2013","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.pharmr.2026.100145_bib76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pnpbp.2013.08.007","article-title":"Influence of aripiprazole pretreatment on the reinforcing effects of methamphetamine in humans","volume":"47","author":"Stoops","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100145_bib77","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/sj.npp.1301353","article-title":"Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration","volume":"32","author":"Wee","year":"2007","journal-title":"Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100145_bib78","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.npp.1301481","article-title":"Bupropion for the treatment of methamphetamine dependence","volume":"33","author":"Elkashef","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib79","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.03.010","article-title":"Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence","volume":"96","author":"Shoptaw","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100145_bib80","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/QAD.0b013e328336e98b","article-title":"Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men","volume":"24","author":"Das","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.pharmr.2026.100145_bib81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2015.01.036","article-title":"Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial","volume":"150","author":"Anderson","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmr.2026.100145_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pbb.2014.11.018","article-title":"Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine","volume":"129","author":"Stoops","year":"2015","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100145_bib83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drugalcdep.2008.09.006","article-title":"Bupropion attenuates methamphetamine self-administration in adult male rats","volume":"100","author":"Reichel","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0022432","article-title":"Comparison of the effects of methamphetamine, bupropion and methylphenidate on the self-administration of methamphetamine by rhesus monkeys","volume":"19","author":"Schindler","year":"2011","journal-title":"Exp Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100145_bib85","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/npp.2015.63","article-title":"Effects of environmental manipulations and treatment with bupropion and risperidone on choice between methamphetamine and food in rhesus monkeys","volume":"40","author":"Banks","year":"2015","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.pharmr.2026.100145_bib86","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.neuropharm.2018.03.021","article-title":"The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine\u2013triggered reinstatement of female rats","volume":"135","author":"Charntikov","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/clpt.2010.307","article-title":"A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction","volume":"89","author":"Galloway","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100145_bib88","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0000000000000207","article-title":"Methamphetamine self-administration in humans during D-amphetamine maintenance","volume":"34","author":"Pike","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.113.208264","article-title":"Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats","volume":"348","author":"Hiranita","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2026.100145_bib90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugalcdep.2015.08.022","article-title":"Effects of 7-day continuous d-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys","volume":"155","author":"Schwienteck","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1360-0443.2008.02437.x","article-title":"A double-blind, placebo-controlled trial of modafinil (200 mg\/day) for methamphetamine dependence","volume":"104","author":"Shearer","year":"2009","journal-title":"Addiction"},{"issue":"1\u20133","key":"10.1016\/j.pharmr.2026.100145_bib92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.drugalcdep.2009.11.023","article-title":"Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence","volume":"109","author":"Heinzerling","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"10.1016\/j.pharmr.2026.100145_bib93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.07.007","article-title":"Modafinil for the treatment of methamphetamine dependence","volume":"120","author":"Anderson","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"2\u20133","key":"10.1016\/j.pharmr.2026.100145_bib94","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.drugalcdep.2009.08.013","article-title":"Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers","volume":"106","author":"De La Garza","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100145_bib95","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1017\/S1461145711000988","article-title":"Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats","volume":"15","author":"Reichel","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmr.2026.100145_bib96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuropharm.2017.12.006","article-title":"Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats","volume":"131","author":"Tunstall","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib97","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/add.13950","article-title":"Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial","volume":"113","author":"Coffin","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib98","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/JCP.0000000000000488","article-title":"Separate and combined effects of naltrexone and extended-release alprazolam on the reinforcing, subject-rated, and cardiovascular effects of methamphetamine","volume":"36","author":"Marks","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FBP.0000000000000671","article-title":"The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward\/punishment sensitivity and methamphetamine\u2019s effects","volume":"33","author":"Jones","year":"2022","journal-title":"Behav Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0022-3565(25)31161-4","article-title":"Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys","volume":"204","author":"Harrigan","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2026.100145_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172671","article-title":"Inhibition of naltrexone on relapse in methamphetamine self-administration and conditioned place preference in rats","volume":"865","author":"Guo","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"5387","key":"10.1016\/j.pharmr.2026.100145_bib103","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.282.5387.298","article-title":"Transition from moderate to excessive drug intake: change in hedonic set point","volume":"282","author":"Ahmed","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2026.100145_bib104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pbb.2017.06.006","article-title":"Modeling the development of drug addiction in male and female animals","volume":"164","author":"Lynch","year":"2018","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib108","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.pbb.2006.09.015","article-title":"Intravenous methamphetamine self-administration in rats: effects of intravenous or intraperitoneal MDMA co-administration","volume":"85","author":"Clemens","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib109","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1124\/jpet.103.061762","article-title":"Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat","volume":"309","author":"McMillan","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pbb.2004.12.003","article-title":"Neither non-contingent electric footshock nor administered corticosterone facilitate the acquisition of methamphetamine self-administration","volume":"80","author":"Moffett","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100145_bib111","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/00001756-200207020-00007","article-title":"Baclofen decreases methamphetamine self-administration in rats","volume":"13","author":"Ranaldi","year":"2002","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib112","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-003-1670-0","article-title":"Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats","volume":"172","author":"Roth","year":"2004","journal-title":"Psychopharmacology"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100145_bib114","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s00213-016-4368-9","article-title":"The effects of sex, estrous cycle, and social contact on cocaine and heroin self-administration in rats","volume":"233","author":"Lacy","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmr.2026.100145_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113329","article-title":"The effects of strain and estrous cycle on heroin- and sugar-maintained responding in female rats","volume":"409","author":"Schmidt","year":"2021","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib116","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00451696","article-title":"The estrous cycle affects cocaine self-administration on a progressive ratio schedule in rats","volume":"98","author":"Roberts","year":"1989","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib117","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2017.1395855","article-title":"Medications for substance use disorders (SUD): emerging approaches","volume":"22","author":"Butelman","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib118","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41398-021-01615-0","article-title":"Translational opportunities in animal and human models to study alcohol use disorder","volume":"11","author":"Nieto","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib119","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41398-025-03473-6","article-title":"Translating medication effects for alcohol use disorder across preclinical, human laboratory, and clinical trial outcomes using meta-analysis","volume":"15","author":"Nieto","year":"2025","journal-title":"Transl Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drugalcdep.2006.03.019","article-title":"Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence","volume":"85","author":"Heinzerling","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib121","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881118817166","article-title":"Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial","volume":"33","author":"Farahzadi","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100145_bib122","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.euroneuro.2010.06.018","article-title":"A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence","volume":"20","author":"Grant","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100145_bib123","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1360-0443.2011.03771.x","article-title":"Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial","volume":"107","author":"Elkashef","year":"2012","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib124","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/fcp.12178","article-title":"Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial","volume":"30","author":"Rezaei","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100145_bib125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/2277-9175.187404","article-title":"Effect of add-on valproate on craving in methamphetamine depended patients: a randomized trial","volume":"5","author":"Kheirabadi","year":"2016","journal-title":"Adv Biomed Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib126","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial","volume":"77","author":"Coffin","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100145_bib127","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: a randomized controlled trial","volume":"68","author":"Colfax","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100145_bib128","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/add.12608","article-title":"Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder","volume":"109","author":"Ling","year":"2014","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40199-015-0092-y","article-title":"Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial","volume":"23","author":"Rezaei","year":"2015","journal-title":"Daru"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100145_bib130","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/JCP.0000000000000408","article-title":"The effect of buprenorphine on methamphetamine cravings","volume":"35","author":"Salehi","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib131","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder","volume":"384","author":"Trivedi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100145_bib132","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41386-019-0336-5","article-title":"Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications","volume":"44","author":"Banks","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmr.2026.100145_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107733","article-title":"Nonhuman animal models of substance use disorders: translational value and utility to basic science","volume":"206","author":"Smith","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib134","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.095380","article-title":"Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone","volume":"317","author":"Negus","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100145_bib135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrn3104","article-title":"Opiate versus psychostimulant addiction: the differences do matter","volume":"12","author":"Badiani","year":"2011","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib136","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/npp.2009.154","article-title":"Effects of extended cocaine access and cocaine withdrawal on choice between cocaine and food in rhesus monkeys","volume":"35","author":"Banks","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/mpr.1929","article-title":"Retention in treatment and therapeutic adherence: How are these associated with therapeutic success? An analysis using real-world data","volume":"31","author":"Dacosta-S\u00e1nchez","year":"2022","journal-title":"Int J Methods Psychiatr Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib138","doi-asserted-by":"crossref","DOI":"10.1177\/009286150904300411","article-title":"Effective strategies for maintaining research participation in clinical trials","volume":"43","author":"Zweben","year":"2009","journal-title":"Drug Inf J"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100145_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2026.100119","article-title":"The role of polysubstance use in the development, maintenance, and treatment of stimulant use disorders","volume":"78","author":"Rough","year":"2026","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2026.100145_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107592","article-title":"A nationally representative analysis of \u201ctwin epidemics\u201d: rising rates of methamphetamine use among persons who use opioids","volume":"204","author":"Strickland","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmr.2026.100145_bib141","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drugpo.2017.07.009","article-title":"Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users","volume":"49","author":"Wang","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib142","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA\u2019s medication development priorities in response to the Opioid Crisis: ten most wanted","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib143","article-title":"Antidepressants versus placebo for generalised anxiety disorder (GAD)","volume":"1","author":"Kopcalic","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100145_bib144","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/a-1714-9097","article-title":"Novel antidepressants in the pipeline (Phase II and III): a systematic review of the US clinical trials registry","volume":"55","author":"Sakurai","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/pedsos.2024-000349","article-title":"Efficacy and safety of centanafadine for ADHD treatment in children: a randomized clinical trial","volume":"1","author":"Ward","year":"2025","journal-title":"Pediatr Open Sci"},{"key":"10.1016\/j.pharmr.2026.100145_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109947","article-title":"Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use","volume":"248","author":"Loya","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmr.2026.100145_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112642","article-title":"A single-blind, randomized, controlled contingency management trial on physiological indices and biomarkers of cardiovascular health in people with cocaine use disorder","volume":"271","author":"Stoops","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmr.2026.100145_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578470","article-title":"Influence of cocaine use reduction on markers of immune function","volume":"397","author":"Stoops","year":"2024","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100145_bib149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1037\/adb0001107","article-title":"Quality-of-life improvements associated with reductions in cocaine-positive urine drug screens","volume":"40","author":"Regnier","year":"2026","journal-title":"Psychol Addict Behav"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100145_bib151","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamapsychiatry.2025.2508","article-title":"Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: a review","volume":"82","author":"Witkiewitz","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100145_bib153","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100145_bib154","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100145_bib155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/pcn.13017","article-title":"Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence","volume":"74","author":"Higuchi","year":"2020","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100145_bib156","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/pcn.12914","article-title":"Nalmefene in alcohol-dependent patients with a high drinking risk: randomized controlled trial","volume":"73","author":"Miyata","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100145_bib157","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pbb.2012.09.025","article-title":"Alternative reinforcer response cost impacts methamphetamine choice in humans","volume":"103","author":"Bennett","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100145_bib158","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1176\/ajp.2006.163.11.1993","article-title":"Contingency management for the treatment of methamphetamine use disorders","volume":"163","author":"Roll","year":"2006","journal-title":"Am J Psychiatry"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:06:58Z","timestamp":1785888418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0031699726000335"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100145","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100145"}}